Schedule II & RFK ·
The 119th Congress (2025–2026) has considered several bills relating to peptide policy. Notable examples include the Peptide Research Access Act, introduced in both chambers in 2025, which would create a streamlined IND pathway for certain categories of peptide research; and provisions in broader FDA reauthorization legislation that address compounding of peptide hormones. None of these bills had passed either chamber as of April 2026. Congressional committees — including House Energy and Commerce, Senate HELP, and the House Oversight Committee — have held hearings addressing peptide policy, generating a record that will shape future legislative efforts.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.